History
Documents created during the development process.
Background information
-
-
Appendix A: Decision paper presented to the Institute's Guidance Executive
-
Appendix A: Decision paper presented to the Institute's Guidance Executive (PDF 105 KB)
-
-
Appendix A: provisional matrix of stakeholders
-
-
Appendix B: proposal paper presented to the Institute's Guidance Executive
-
Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 285 KB)
-
-
-
Summary of the responses from this consultation
-
Review decision - December 2008: table of comments (PDF 43 KB)
-
-
Provisional matrix of consultees and commentators (MSWord 67 KB)
Psoriasis - infliximab: Final appraisal determination and comments on ACD
-
Psoriasis - infliximab: Final appraisal determination and comments on ACD information
-
Psoriasis - infliximab: Final appraisal determination
-
Psoriasis - infliximab: Final appraisal determination (PDF 86 KB)
-
Response to consultee, commentator and public comments on the ACD and comments from website consultation
-
-
Consultee and commentator comments on the ACD
-
Commentators
-
Wyeth Pharmaceuticals
-
-
Merck Serono
-
-
Cochrane Skin Group
-
-
Professional and patient groups
-
Royal College of Physicians
-
-
Royal College of Paediatrics and Child Health
-
-
The Psoriasis Association
-
-
British Association of Dermatologists
-
-
Schering Plough Ltd
-
-
Expert comments on the ACD: Ms Karina Jackson, Clinical Expert nominated by the British Dermatological Nursing Group
-
Psoriasis - infliximab: Appraisal Consultation Document
Psoriasis - infliximab: Evaluation report
-
Psoriasis - infliximab: Evaluation report
-
Psoriasis - infliximab: Schering-Plough Ltd
-
-
Psoriasis - infliximab: Evidence review group report
-
Psoriasis - infliximab: Evidence review group report (PDF 445 KB)
-
Pre-meeting briefing
-
-
Psoriasis - infliximab: Non-manufacturer submissions
-
The Psoriasis Association
-
-
Psoriatic Anthropathy Alliance
-
-
British Association of Dermatologists
-
-
British Dermatological Nursing Group
-
-
Royal College of General Practitioners
-
-
Royal College of Physicians
-
-
Psoriasis - infliximab: Manufacturer response to clarification letter
-
Manufacturer response A
-
-
Manufacturer response B
-
-
NICE clarification letter
-
-
Psoriasis - infliximab: Expert written personal statements
-
Griffiths
-
-
Barker
-
-
Jackson
-
-
Edwards
-
-
Jobling
-
Medicines concordance: Final scope
-
Medicines concordance: Final scope
-
Medicines concordance: Final scope
-
Medicines concordance: Final scope
-
Comments on draft scope and matrix and the Institute's response
-
Comments on draft scope and matrix and the Institute's response
-
Comments on draft scope and matrix and the Institute's response (PDF 51 KB)
Psoriasis - infliximab: Final scope archive
-
Psoriasis - infliximab: Final scope archive
-